Antidote Technologies, a US and UK based digital health company, raised $23M in funding.
The round was led by LBO France, which is investing $10m through its Digital Health 2 fund, with participation from existing investors Merck Global Health Innovation Fund, Smedvig Capital, and Octopus Ventures, who are investing $13.2m in total. In conjunction with the funding, Sebastien Woynar and Franck Noiret of LBO France will join the Antidote Board as a director and an observer, respectively.
The company intends to use the funds to enhance its clinical trial search engine, launch new products and services (including data insights), and expand its presence internationally.
Led by Laurent Schockmel, CEO, Antidote is a digital health company which uses precision recruitment to match the right patients with the right trials. This is achieved through the integration of data-driven technologies, digital expertise, deep domain experience, an extensive diverse partner network, and personalized patient and site services. Antidote was launched as TrialReach and is based in New York, NY, Carmel, IN, and London, U.K.
FinSMEs
03/06/2021